Sangamo Therapeutics: Challenging Road Ahead After Pfizer Exit
Pfizer terminated partnership with Sangamo on hemophilia A gene therapy despite positive Phase 3 data. Find out why SGMO ...
BioSpace2d
AceLink’s Fabry Hopeful Shows Potential in Mid-Stage Study
AceLink is advancing a small-molecule treatment option for Fabry disease, which could provide a more convenient alternative ...
Sangamo reports updated data for gene therapy candidate ST-920
Sangamo (SGMO) reported positive updated data from a Phase 1/2 study of its gene therapy candidate ST-920 in the treatment of Fabry disease. Read more here.
Sangamo reports positive Fabry disease gene therapy results
RICHMOND, Calif. - Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic medicine company with a market capitalization of $263 million, has announced promising updated results from its Phase 1/2 STAAR ...
Sangamo announces updated data from STAAR study
Sangamo (SGMO) announced updated data from the Phase 1/2 STAAR study evaluating isaralgagene civaparvovec, or ST-920, a wholly owned gene ...